A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson disease(STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily on Parkinson disease (PD) disability. Background: Isradipine, a dihydropyridine calcium channel antagonist with excellent penetration…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy
Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…Reduction of neuroinflammation by selective inhibition of the N-type calcium channel is beneficial in various animal models of neurodegeneration, here in the SOD1G93A transgenic mouse model of ALS
Objective: Neuroinflammation is a pathological hallmark of several neurodegenerative diseases. We speculated that reduction of calcium ion influx specifically in neurons should reduce inflammatory cellular…Rose Anthocyanins protect against Parkinson’s pathophysiology: Behavioral and biochemical changes in young Drosophila
Objective: To test the hypothesis that Rose Anthocyanins, owing to their biological properties in vitro, protect against Parkinson’s pathophysiology in young Drosophila melanogaster. Background: Anthocyanins…Oligosymptomatic Fahr’s syndrome (2 clinical cases)
Objective: Two clinical cases of Fahr`s syndrome was presented. Background: Fahr's syndrome (FS) or secondary bilateral striatopallidodentate calcinosis is a rare neurological disorder characterized by…Improvement in chorea and function in a patient with dystonia-choreoathetosis cerebral palsy after treatment with bilateral pallidal deep brain stimulation
Objective: We describe and demonstrate by video a patient with dystonia-choreoathetosis cerebral palsy treated with bilateral pallidal deep brain stimulation (DBS). Background: Dystonia-choreoathetosis cerebral palsy…
- « Previous Page
- 1
- …
- 146
- 147
- 148
- 149
- 150
- …
- 177
- Next Page »